Identification of Tractable Drug-Like elF4AI Inhibitors with Potent Anti-Tumor…

Clinical efficacy of targeted signaling inhibitors for hematologic malignancies is limited by outgrowth of subpopulations with alternative pathways independent of the drug target. The eIF4F complex responsible for translation initiation is a convergence point for cancer-promoting signaling pathways and its inhibition leads to decreased expression of key oncoproteins and apoptosis. Read more “Identification of Tractable Drug-Like elF4AI Inhibitors with Potent Anti-Tumor Activity” →